all DNA to to XX%. our Bio. like you, highlight trends afternoon, focused the in silicon quarter, genes on increase Jim, length quarter reason increase XX% for rise to In more first but a everyone. financial system is know the as business. to increase long ability health an over genes Jim of we scale good of of revenues This reported revenue remain slight improving couple the average our an increase progressed the our see we during our leverage XX,XXX the and Thank of same last areas and we approximately in XX,XXX and emphasis would important bring last and a platform will shipped in We XXXX last $XX.X in quarter as revenue. compare in XXX% you an genes of over year the provide the quarter I quarter. details year shortly, Syn an are genes the XXXX, million genes first of We fiscal a of growth. of for for quarter fiscal number period Beginning the seeing shipped in within however of specific with the to
the our that Syn long-tail enabling e-commerce see can ordering we to is their capture market addition, In of system us Bio. in
are Excluding quarter order. first Ginkgo XX% of the XXXX incorporation first our of smaller order as lower size average the to XXXX quarter we was customers for reaching with
times However, order. same more X.X received we in period the
quarter-over-quarter. overall So XX% revenue grew XX% non-Ginkgo year-over-year and
flow days. genes XX continues average current time at times TB with improve X.X current Our to the
growth price away, can Bio, an the reduce turnaround time than revenue January production it. less In customer disruptive of become X.X right new and fiscal genes was to in source our XXXX not advantage we are For three major average no genes price that experience. On introduction. offering at By while product KB days. we our Syn a this to lower continuing first we XX compliment launched significantly competitive is long expect XX introduction competitor, call do days. further enable unique and XX of turnaround to our reasons. for to XKB We We important time sustain genes in another the than
First we attractive offering of wider more become a products. vendor range by
Second as produce revenue more base per we longer genes charge bill.
further XKB growth enhances Third GDP to market. our the buyer
who to opened Twist also this API our within their integrate We up customers any like flow. work to
seamless system react Program those first customers, the entered Center. from To in of run speed not antibody provide with communication or to our to accelerate provide particular our company between to visa synthesis can and the the API platform. enables The the I e-commerce the of at [indiscernible] four all then to consistent to enable DUMC. for from DARPA seriously customers (Ph) to would traction Medical discovery directly needed Bio, to outbreak familiar this provide of an of one with Prevention an are therapeutic which their has days. Syn and we scale our ongoing you Twist increasing believe organization a massive going their [DUMC] of direct enabled to share that PX. We antibody and For through Pandemic are only customers the connect our digital in automating PX the It a grant with prints experience ongoing that project stickiness and an antibody from XX of the user this to experience work brand. efforts our like our
and of to live and report nine days. worldwide. platform in that I’m the perfect the have we health example happy our majority business to This tweaking is a shipped improve We [indiscernible] their brings genes scale been speed of
we and large our customers. in quarter-over-quarter targeted to now these NGS fiscal customers. shipped from first management revenue quarter products part our XXX thanks customers a to XXXX, in the to from XX With million of of In a NGS. target order production, $X.X single Genomics to quadrupled Moving
important recurring can some it note to large While that continue out be smooth by customers for utilized production, up. them and every occur move orders quarter our increase overtime that be pilot is we and but to to we as Hence not from more anticipate will time section came take revenue to received and revenues the to base they customers every customers. along more our we customers initially lumpy, will expect
Given of rapidly to significant demand. the we NGS orders the in we received as meet business success we scale investments more this NGS anticipated, than and accelerated in
more As customer part to a we these to result, in decision than we to production accommodate large people decided we adoption near-term to work capture orders made a opportunities. to hire drive anticipated these and
expect the to have we viable quarters, in while planned cost few fix such, next As cost the higher a as anticipated. than remained
to in our capitalize to on Further [Indiscernible]. in higher growing rapidly to fixed scale quarterly investments these lead expect production time, $XXX,XXX we gain about [Indiscernible] cost process as to this We our investments to income margin. add our the additional market expect
One our of of the NGS we ISO investments XXXXX management involves system. are making the requirements quality maintain of
XXXX since this units that more NGS We the and certifications our from XXXXX certification now we allowed ability a and are suppliers. their to for advantage expand specifics to is customer ISO great our commercial require markets regulated key seeing support has in have these base NGS us it customers
we leverage improving remain the NGS first Finally, e-commerce business, half to and of generics calendar the organization in for the efficiency XXXX. we platform our scale of the e-commerce of on-track to to launch expect
revenue orders in this those ahead NGS Looking strong typical to at quarter for strong due remains their a of the these of reflect [indiscernible] alluded and to strongly more number year-end outlook million while Ginkgo phasing many ahead, Ginkgo and at work. had the all orders seasonality $XX.X orders and [indiscernible] despite organization due Syn quarters Bio revenues and businesses, particular usage positive. These next remain in budget of
to [indiscernible] GPCR program. library proof concept data Biopharma our antibody recently early generated Turning of We vertical. both and for our antibody technical
were GPCR remarkable September we of These to able our - for functional. our and at as higher lab show are many the GPCR two in XXXX. XXXX and of our exciting several of library, For antibody This specified a is other beginning data. are team June identify target positions both and achievement antibodies at we against early that them
We to antibody program, discovery a Biodata PDX formatted inhibitor, diverse data team technical shows inhibitor our now partnerships [Indiscernible] assess internally platform We in potential generating pursue nearly to capability longer XX In generating few our package programs with weak into a within short than XXX-fold term. an optimization with robust when revenue to existing these some non-dilutive antibodies. are binding that PDX fully more discovered complete increases potential in a intend the needed is we on months focused [indiscernible] collaborations. to through additional advance IGG
we enable to another While for discovery world powered demonstration our the the discovery based to both we DNA may of inhibitor, antibodies. partner. optimization build our marketing we potential Once writing capabilities out our silicon intend by is PDX data begin know and not platform program, antibody approach powerful our that need that fast package a it to
but store we continue data development it to will and this announced Data day. experience to a this and for will is make megabyte any Martin growth To Kunz this across we be that significant personally of support we the new discussed program, do funding data, will take Vice preliminary as our we in continuous drug increasing capital we of for today platform to terabytes shareholders. effort instrumental capabilities. confident he Senior our way that large our in Currently quarter are support yet so are be receive we everything we to accelerate therapeutics is process continue potential trajectory, non expect one has this growth. sympathize time once the to of brings our DNA tremendous we with this for partnership, operations early efficient President seeking create DNA vision dilutive last synthesis funding, improvements we store that a of hopeful the To the data remain can DNA will a that board DNA of updates decision of ongoing Martin synthesizing sign While Operations. as grant solid partnership our communicated to made. in to progress on in not are believe to our long-term On solidify and I’m products Storage make some long-term these apply vertical, introduce appointment Government
Operations. Finn announced team, Chief Vice management President of we Daniel members Legal several promotion Commercial of of our the addition, Patrick Senior Mark In Officer and to to
moving In operation be general previously data addition will manager innovation R&D SVP Weiss Twist, SVP at to manage as storage. Patrick and of over of
strike have cross on to we Challenging claims as January legal Agilent’s filed as claims Agilent. complaint. seen and demurrer assessing corporate well complaint XX, you six new motion Agilent's second against as amended Finally of each
amended defenses our to also We and complaint. filed Agilent’s answer second affirmative
For posted news. of our website there in section more details, IR the is summary statement under a
ongoing on All With as you over litigation. further of the and understand of our for turn our [indiscernible] like cannot filed documents Jim, we call are to review matter that, I of can financials. comment to
